Nanomedicine Revives an Anti Cancer and Antiangiogenic Drug
Targeting angiogenesis - the formation of new blood vessels - is an important modality in cancer therapy. Cutting off blood supply to tumors can potentially induce dormancy and prevent further tumor progression and spreading. Over the last decade numerous compounds targeting angiogenic pathways were developed, however, their clinical use is often limited by poor pharmacological properties. Nanotechnology can be exploited to address drug-related limitations and provide new mechanisms for drug activity, biodistribution, toxicity and pharmacological profiles.
In this seminar we present the development of Lodamin - a rationally designed drug and polymer-conjugate of the antiangiogenic molecule TNP-470. The nanomicelle structure of Lodamin provides many advantages that dramatically improve TNP-470's properties such as oral availability and safety, which were the main clinical limitations in the clinic. The broad spectrum activity of Lodamin was demonstrated in several preclinical models of angiogenesis, cancer and metastasis and is now being developed for clinical use in oncology and ophthalmology. Lodamin's rational design demonstrates how nanomedicine can be used to overcome previously impassable obstacles on the path to new therapies.